Insider Buying: Kodiak Sciences (NASDAQ:KOD) Director Buys $60,529,244.82 in Stock

Key Points

• Director Bros. Advisors LP Baker bought 681,866 Kodiak Sciences shares at an average $88.77 each, investing approximately $60.5 million and increasing direct ownership by 3.5% to 20.16 million shares.
• Kodiak shares rose 4.0% to $94.80, supported by positive Phase 3 DAYBREAK results for Zenkuda in wet age-related macular degeneration and progress toward a potential Biologics License Application filing.
• Despite bullish analyst revisions and a consensus “Moderate Buy” rating, Kodiak remains a cash-burning, pre-revenue biotech; potential fundraising could dilute shareholders, while elevated put-option activity signals pullback concerns after the sharp rally.

Kodiak Sciences Inc. (NASDAQ:KOD - Get Free Report) Director Bros. Advisors Lp Baker acquired 681,866 shares of Kodiak Sciences stock in a transaction that occurred on Monday, September 28th. The stock was acquired at an average cost of $88.77 per share, for a total transaction of $60,529,244.82. Following the completion of the purchase, the director directly owned 20,159,386 shares of the company's stock, valued at $1,789,548,695.22. This represents a 3.50% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Bros. Advisors Lp Baker also recently made the following trade(s):

• On Monday, September 28th, Bros. Advisors Lp Baker bought 807,840 shares of Kodiak Sciences stock. The stock was purchased at an average cost of $72.57 per share, with a total value of $58,624,948.80.
• On Monday, September 28th, Bros. Advisors Lp Baker purchased 418,323 shares of Kodiak Sciences stock. The shares were bought at an average price of $83.58 per share, with a total value of $34,963,436.34.
• On Tuesday, September 29th, Bros. Advisors Lp Baker purchased 33,726 shares of Kodiak Sciences stock. The shares were bought at an average price of $85.05 per share, with a total value of $2,868,396.30.

Kodiak Sciences Trading Up 4.0%

Shares of NASDAQ KOD traded up $3.68 during mid-day trading on Wednesday, hitting $94.80. The company had a trading volume of 4,897,441 shares, compared to its average volume of 1,094,203. Kodiak Sciences Inc. has a 1 year low of $10.94 and a 1 year high of $98.80. The stock's 50-day moving average price is $40.26 and its 200-day moving average price is $38.27. The company has a market capitalization of $5.96 billion, a price-to-earnings ratio of -22.63 and a beta of 2.18.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.96) by ($0.09). As a group, equities research analysts forecast that Kodiak Sciences Inc. will post -3.89 earnings per share for the current year.

Trending Headlines about Kodiak Sciences

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: Kodiak said Zenkuda and tabirafusp-ted achieved the primary endpoints in the Phase 3 DAYBREAK study for wet age-related macular degeneration, reportedly matching Eylea on efficacy while supporting the potential benefits of longer-lasting eye treatments. The results are the main catalyst behind the stock’s sharp increase. KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears
• Positive Sentiment: The company is advancing Zenkuda toward a Biologics License Application filing, strengthening expectations that Kodiak could move from a development-stage biotech toward a commercial product opportunity. Kodiak Sciences Inc. Advances Zenkuda Toward Filing
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $96 price target while raising its long-term EPS forecasts, including estimates of $1.76 for fiscal 2029 and $5.81 for fiscal 2030. It also improved its fiscal 2028 loss estimate, though its fiscal 2027 loss forecast worsened slightly. HC Wainwright Kodiak Sciences analyst estimates
• Positive Sentiment: Additional analyst coverage from Lifesci Capital, UBS Group and HC Wainwright has pointed to higher valuation potential following the clinical update. Kodiak Sciences Stock Gets Price Target Boost from Lifesci Capital
• Neutral Sentiment: Unusually high put-option buying indicates that some traders are hedging or positioning for a pullback after the sharp rally, but it does not by itself establish a fundamental change in the company’s outlook. Kodiak Sciences Stock Sees Unusually High Put Option Buying
• Negative Sentiment: Despite the clinical success, Kodiak remains a cash-burning biotech with no revenue and ongoing development expenses. Analysts and commentators warn that a potential share offering could fund operations but dilute existing shareholders, making the stock’s sharp repricing difficult to chase. A $32 Biotech Became a $90 Biotech Overnight

Institutional Investors Weigh In On Kodiak Sciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Algert Global LLC grew its position in Kodiak Sciences by 26.1% in the 2nd quarter. Algert Global LLC now owns 186,476 shares of the company's stock valued at $7,265,000 after acquiring an additional 38,546 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Kodiak Sciences by 31.8% in the 1st quarter. The Manufacturers Life Insurance Company now owns 120,629 shares of the company's stock valued at $4,598,000 after acquiring an additional 29,121 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in Kodiak Sciences in the second quarter valued at $1,072,000. Bank of America Corp DE purchased a new position in shares of Kodiak Sciences during the second quarter worth about $14,949,000. Finally, California State Teachers Retirement System grew its holdings in shares of Kodiak Sciences by 1,358.9% during the first quarter. California State Teachers Retirement System now owns 29,396 shares of the company's stock worth $1,121,000 after purchasing an additional 27,381 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company's stock.

Analyst Upgrades and Downgrades

KOD has been the subject of a number of research reports. Wall Street Zen lowered shares of Kodiak Sciences from a "sell" rating to a "strong sell" rating in a research report on Saturday. JPMorgan Chase & Co. boosted their target price on Kodiak Sciences from $56.00 to $66.00 and gave the stock an "overweight" rating in a research report on Monday, August 3rd. Lifesci Capital raised their target price on shares of Kodiak Sciences from $85.00 to $145.00 and gave the company an "outperform" rating in a report on Monday. UBS Group upped their price target on shares of Kodiak Sciences from $80.00 to $120.00 and gave the company a "buy" rating in a research note on Monday. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Kodiak Sciences in a research report on Friday, July 10th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $100.43.

Kodiak Sciences Company Profile

Kodiak Sciences Inc NASDAQ: KOD is a biopharmaceutical company focused on developing therapies for retinal diseases and other conditions affecting the eye. The company's research is centered on antibody biopolymer conjugates, a technology designed to extend the duration of action of biologic medicines in ocular tissues and potentially reduce the frequency of administration.

Its lead development program has been tarcocimab tedromer, also known as KSI-301, an anti-vascular endothelial growth factor (VEGF) therapy investigated for retinal vascular diseases, including diabetic macular edema, diabetic retinopathy and neovascular age-related macular degeneration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.